|
Status |
Public on Oct 30, 2014 |
Title |
Global ChIP-seq Normalization Reveals Epigenome Modulations |
Organisms |
Drosophila melanogaster; Homo sapiens |
Experiment type |
Genome binding/occupancy profiling by high throughput sequencing
|
Summary |
Epigenomic profiling by ChIP-seq is a prevailing methodology used to investigate chromatin-based regulation in biological systems, such as human disease, yet the lack of an empirical methodology to normalize amongst experiments has limited the usefulness of this technique. Here we describe a “spike-in” normalization method that allows the quantitative comparison of histone modification status across cell populations using defined quantities of a reference epigenome. We demonstrate the utility of this method in measuring epigenomic changes following chemical perturbations and show how control normalization of ChIP-seq experiments enables discovery of disease-relevant changes in histone modification occupancy.
|
|
|
Overall design |
ChIP-Seq of histone modifications H3K79me2 and H3K4me3 in human samples treated with EPZ-5676 with/without reference epigenome spike-in.
|
|
|
Contributor(s) |
Guenther MG, Chen MW, Orlando DA, Olson ER |
Citation(s) |
25437568 |
|
Submission date |
Aug 05, 2014 |
Last update date |
May 15, 2019 |
Contact name |
Eric Olson |
Organization name |
Syros Pharmaceuticals
|
Street address |
480 Arsenal Street
|
City |
Watertown |
State/province |
MA |
ZIP/Postal code |
02472 |
Country |
USA |
|
|
Platforms (2) |
GPL11154 |
Illumina HiSeq 2000 (Homo sapiens) |
GPL13304 |
Illumina HiSeq 2000 (Drosophila melanogaster) |
|
Samples (48)
|
|
Relations |
BioProject |
PRJNA257491 |
SRA |
SRP045268 |